12:12 PM EST, 01/13/2025 (MT Newswires) -- Blueprint Medicines ( BPMC ) said Monday it now projects the peak revenue opportunity for its systemic mastocytosis franchise at $4 billion, with Ayvakit likely to achieve annual revenue of $2 billion by 2030.

The company said its BLU-808 treatment for mast cell disorders was well-tolerated at all doses tested in a phase 1 trial in healthy volunteers.

"The results show that BLU-808 performed consistently, with dose-dependent outcomes, including rapid, robust and sustained reductions in serum tryptase across a range of doses, which reinforce the potential for tunable treatment," Blueprint Medicines ( BPMC ) Chief Scientific Officer Percy Carter said in a press release Sunday.

The company continues to expect product revenue from Ayvakit between $475 million and $480 million for full-year 2024.

Blueprint Medicines ( BPMC ) shares were up nearly 10% in recent trading.

Price: 95.82, Change: +8.39, Percent Change: +9.60